

**Ohio Department of Medicaid (ODM)
Drug Utilization Review (DUR) Board
Quarterly Meeting
February 17, 2015**

The quarterly meeting of the ODM DUR Board was called to order at 12:08 PM in rooms West B&C on the 31st Floor of the Riffe Center, 77 S. High Street, Columbus, Ohio. J. Layne Moore, MD, presided. The following Board members were present:

David Brookover, RPh
Robert Kubasak, RPh
J. Layne Moore, MD
Donald Sullivan, RPh, PhD

Also present from ODM were Margaret Scott, RPh, DUR Administrator; Jill Griffith, RPh, DUR Director; Mike Howcroft RPh, Patti Nussle RPh, and Travis Pinkstaff, PharmD student. Approximately 12 observers were present, most representing pharmaceutical manufacturers.

Reading, Correction & Approval of Previous Minutes:

The November 18th, 2014, DUR Board minutes were approved. (1st D. Brookover, 2nd R. Kubasak).

Health Plan Policy:

M. Scott reviewed the Conflict of Interest policy and Board Members signed the Conflict of Interest Statement. M. Scott announced the budget process is underway. Medicaid will keep the expansion population and new elements of patient responsibility such as copays are expected.

DUR Committee Report:

In November the DUR Committee completed a review of patients who appear to be taking Abilify more than once daily. Abilify has a 72-hour half-life and is FDA-approved only for once-daily dosing. The Board reviewed and approved the Abilify Intervention letter as well as reviewed an educational insert released by the Department of Mental Health and Addiction Services that will be re-purposed for Medicaid. The board was asked to consider a quantity limit of 30 tablets per 30 day supply based on the DUR Committee findings and based on the Medicaid managed care plans' 1 tab/day limit of Abilify instituted by Nationwide Children's Hospital Partners for Kids in 2013 and 2014. Discussion ensued. Prior Authorization will be available to those who require more than 30 tablets in 30 days. Psychiatrists are exempt from any requirement to obtain prior authorization for the drug, but are not exempt from quantity limits.

A review of Seroquel XR utilization is an upcoming task of the DUR Committee.

In December the DUR Committee also reviewed a report on counts of patients with what is best described as high risk poly pharmacy, which are patients on 6, 7 or 8 different CNS drugs concurrently. The CNS

drugs include: narcotics, anticonvulsants, antipsychotics, anti-anxiety, muscle relaxants, serotonin-norepinephrine re-uptake inhibitors, tricyclic antidepressants and sedative hypnotics.

In January the DUR Committee completed a review of 387 patients who are taking 6, 7 or 8 CNS drugs concurrently.

Each month, the DUR Committee continues its monthly monitoring of patients on high morphine equivalent doses by reviewing updated patient profiles. D. Sullivan updated the Board on a new Ohio law that requires prescribers to check OARRS before prescribing, effective April 1, 2015.

Unfinished Business:

M. Scott discussed that the pharmacy benefit manager (PBM) services contract for the fee-for-service population is coming to an end, and an RFP has been issued to solicit proposals for PBM services. DUR services are included as an optional service that can be fulfilled by the vendor awarded the new contract that results from the RFP. The state will evaluate responses.

M. Howcroft provided updates on antipsychotic use in long-term care facilities and psychotropic use in children. The board discussed Ohio progress and possible outcomes from the project. Mina Chang, PhD with Ohio Medicaid will present a larger update at the May 19th DUR Board meeting. The Governor's Cabinet Opiate Action Team continues to work on guideline development for acute pain prescribing, with a goal to reduce the number of doses prescribed.

Announcements:

M. Scott announced that the second quarter meeting will be on May 19th 2015 (room to be determined).

Adjournment:

L. Moore adjourned the meeting at 12:46 PM. (1st D. Brookover, 2nd D. Sullivan).

Respectfully submitted:

Jill RK Griffith BS, PharmD, DUR Program Director